Tuesday, May 01, 2007 11:06:48 AM
http://www.balchem.com/core/newsletter_details.asp?ArticleID=323
Balchem Completes Acquisition of Akzo Nobel’s European-based Choline Chloride and Methylamines Businesses at Marano Ticino, Italy
New Hampton, New York. May 1, 2007. Balchem Corporation (NASDAQ:BCPC) today announced the completion of its acquisition of the European-based choline chloride and methylamines businesses of Akzo Nobel Chemicals S.p.A. in Marano Ticino. Balchem and Akzo Nobel originally announced this acquisition on April 2, 2007. This facility and business will be operated by Balchem Italia, S.r.l. and employs approximately 75 people in Marano Ticino. In addition, a three person sales force operating out of Balchem Trading B.V. in the Netherlands will have primary responsibility for the marketing, sales and distribution of certain products produced at the facility. In 2006, the Akzo Nobel Marano Ticino business had approximately $35 million dollars (U.S.) in sales.
Balchem is a worldwide leader in the production and sales of various choline chloride products, which are nutritional additives to animal feed and human food products. Methylamines are a primary building block for the manufacture of choline products and have several other chemical applications.
Dino Rossi, Balchem’s President, CEO and Chairman added, “The closing of this transaction marks a tremendous step forward in the evolution and growth of Balchem. This acquisition provides a direct platform for Balchem to meet the growing market needs of methylamines, choline chloride and derivative products for customers via improved global sourcing, regulatory support, marketing and distribution capabilities.”
For more details regarding the closing of this transaction, including the provisional purchase price, see Balchem's Form 8-K filing to be submitted to US Securities and Exchange Commission (www.sec.gov).
Your trading and investment choices should be the result of your own due diligence.
Recent BCPC News
- Balchem Corporation Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/03/2024 11:00:00 AM
- New York Jets Announce Multi-Year Partnership with VitaCholine® • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Balchem Corporation to Attend the BMO 19th Annual Global Farm to Market Conference on May 16, 2024 • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Balchem Corporation Releases 2023 Sustainability Report • GlobeNewswire Inc. • 04/22/2024 11:00:00 AM
- Balchem Corporation Announces Quarterly Conference Call for First Quarter Financial Results on May 3, 2024 • GlobeNewswire Inc. • 04/19/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 11:18:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:30:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:32:14 PM
- Balchem Corporation to Participate at the BNP Paribas Exane 12th Consumer Ingredients Conference on March 14, 2024 • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 09:58:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:57:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:11:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 09:41:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 09:37:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/22/2024 10:08:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/21/2024 10:12:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/21/2024 10:12:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/21/2024 09:55:41 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/16/2024 10:26:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 12:14:27 PM
- Balchem Corporation Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/16/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 12:09:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:58:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:55:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:00:07 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM